Lumenis, the inventor of IPL, presents the first and only IPL FDA-approved for the management of dry eye disease due to MGD.
Introducing OptiLight – a bright solution for dry eyes. OptiLight elevates dry eye management with Lumenis’ patented Optimal Pulse Technology (OPT™) and user-centered design. Get the safe, precise, elegant procedure you want and the comfortable, effective therapy your patients need to manage dry eye disease with OptiLight.
THE FIRST AND ONLY IPL FDA APPROVED FOR DRY EYE MANAGEMENT
WATCH OPTILIGHT VIDEO
WHAT THE EXPERTS ARE SAYING
STOP THE DRY EYE
VICIOUS CYCLE OF INFLAMMATION
Reduce Inflammatory Mediators
Decrease the level of pro-inflammatory mediators to inhibit inflammation
Improve Tear Breakup Time
Significantly boost tear break up time and decrease osmolarity
Alleviate Abnormal Blood Vessels
Destroy the abnormal blood vessels that perpetuate inflammation
Restore Meibomian Glands
Improve meibomian gland morphology and functionality
Decrease Demodex
Decrease the population of Demodex mites, which stimulate infection and boost the bacterial load on eyelids.
LUMENIS’ BRIGHT SOLUTION:
BACKED BY PEER-REVIEWED CLINICAL STUDIES
Effective multifactorial treatment for a multifactorial disease
ELEVATING
YOUR DRY EYE PRACTICE
Light-based, quick, 15-Minute Procedure
Each OptiLight session takes about 15 minutes, so you can easily integrate OptiLight into your practice.
With a seamless workflow and just 4 easy-to-perform sessions, OptiLight is an essential tool in your dry eye toolkit.
Elevate clinical effectiveness, practice efficiency and business growth with OptiLight.